Biontech Se Sponsored Adr Stock News

German vaccine maker BioNTech, which developed the first widely approved shot against COVID-19 together with Pfizer, unveiled plans Wednesday to establish manufacturing facilities in Africa that would

BioNTech SE said Wednesday it is developing turkey mRNA manufacturing facilities based on a container solution in an effort to promote scalable vaccine production in Africa. The company is expecting to deliver the first BioNTainer in the second half, comprising one drug substance and one formulation module. "Each module is built of six ISO sized containers (2.6m x 2.4m x 12m). This allows for mRNA vaccine production in bulk (mRNA manufacturing and formulation), while fill-and-finish will be taken over by local partners. Each BioNTainer is a clean room which BioNTech equips with state-of-the-art manufacturing solutions," the company said in a statement. Two modules will require 800 square meters of space and will have an initial capacity to produce up to 50 million doses of the COVID vaccine BioNTech developed with Pfizer Inc. . The company is expecting to ship BioNTainers to Rwanda, Senegal and potentially South Africa in close coordination with the respective country and the African Union.

MAINZ, Germany, February 16, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) has taken a next step to improve vaccine supply in Africa. The company has introduced its approach to establishing scalable vaccine production by developing and delivering turnkey mRNA manufacturing facilities based on a container solution. At a high-level meeting at BioNTech’s new manufacturing facility in Marburg and at the invitation of kENUP Foundation, the company presented the container solution named “BioNTainer” to key partners.

BioNTech SE (NASDAQ: BNTX), which developed the first widely approved COVID-19 shot together with Pfizer Inc (NYSE: PFE), unveiled plans to establish manufacturing facilities in Africa to boost t

BioNTech Chief Operating Officer Sierk Poetting discusses the vaccine maker's plans to ship mRNA vaccine factory kits to increase production of vaccines on the continent.

BioNTech SE BNTX, +5.77% said Wednesday it is developing turkey mRNA manufacturing facilities based on a container solution in an effort to promote scalable vaccine production in Africa. The company i

MAINZ, Germany, February 15, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will welcome project partners, among them official representatives, in Marburg to conduct a high-level meeting on sustainable vaccine manufacturing in the African Union. The meeting initiated by the kENUP foundation will be followed by public statements on February 16, 2022 at approx. 11.30 CET / 05.30 ET from the following participants:

What will result from the anticipated upcoming FDA meeting?

What will result from the anticipated upcoming FDA meeting?

COVID-19 vaccine boosters from Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc (NASDAQ: MRNA ) become less effective after four months but still provide significant protection against hospitalization, a CDC study found. While vaccine efficacy was still strong two months after a booster shot, it declined significantly after four months. Efficacy against COVID-19associated emergency department visits and Full story available on Benzinga.com

A delay for Pfizer and BioNTech appears to be weighing on all vaccine stocks.

BioNTech SE (NASDAQ: BNTX ) is trading lower Monday morning after the U.S. Food and Drug Administration (FDA) requested additional data before approving its COVID-19 vaccine for children aged six months to four years old. Pfizer Inc (NYSE: PFE ) and BioNTech extended their rolling submission to the FDA seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 vaccine to include the aforementioned age group. In December, the two … Full story available on Benzinga.com

The FDA has postponed the Advisory Committee meeting scheduled for Pfizer Inc (NASDAQ: PFE ) / BioNTech SE''s (NASDAQ: BNTX ) COVID-19 vaccine in children six months through 4 years of age, initially scheduled for February 15. The decision comes after a preliminary assessment of data submitted by Pfizer / BioNTech to request emergency authorization, and the agency thinks it needed more data before weighing in on approval. The extension allows the FDA time to receive updated data on the two and three-dose regimen, Pfizer said, while … Full story available on Benzinga.com

FRANKFURT, Germany Frank-Walter Steinmeier was elected to a second term as Germanys president on Sunday, February 13, as a special assembly voted the veteran politician, seen as a symbol of consensus and continuity, back in to the prominent yet largely ceremonial post. Steinmeiers election by secret ballot by a majority of the assembly for another five years was widely expected, amid broad support from most of Germanys major parties during a time of global turmoil and following a recent change of government. Chancellor Olaf Scholz, noting the COVID-19 pandemic and the Ukraine crisis, called Steinmeier the right president at exactly the right time. In his acceptance speech, Steinmeier criticized Russias military build-up. I can only warn (President Vladimir Putin) Dont underestimate the strength of democracy. A top government aide during Gerhard Schroeders chancellorship and a foreign minister under Angela Merkel, Steinmeier is the 12th person all men to hold the office in the post-war era.

Agency needs more time to review data Related Stocks: PFE , BNTX ,